Clinical Trial Update: A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study [Phase 3]

View source ↗

Summary

A Phase 3 non-inferiority study evaluated lot-to-lot consistency across three lots of GSK's 10-valent pneumococcal conjugate vaccine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Synflorix (10-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Streptococcal | Phase 3 | Status: COMPLETED